First AI-generated small molecule drug enters Phase II trial
European Pharmaceutical Review
JUNE 29, 2023
The world’s first AI-generated anti-fibrotic small molecule inhibitor drug has been administered to the first human patients. Phase II clinical trials in the US and China are now underway for INS018_055, Insilico Medicine’s potentially first-in-class oral drug candidate. Patients will be divided into four parallel cohorts.
Let's personalize your content